Search hospitals > Maryland > Salisbury
Peninsula Regional Medical Center
Claim this profileSalisbury, Maryland 21801
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
148 reported clinical trials
6 medical researchers
Summary
Peninsula Regional Medical Center is a medical facility located in Salisbury, Maryland. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Peninsula Regional Medical Center is involved with conducting 148 clinical trials across 189 conditions. There are 6 research doctors associated with this hospital, such as Justinian R. Ngaiza, John R. Mansueti, Zeinab Abou Yehia, and Steven Hearne, MD.Area of expertise
1Cancer
Global LeaderStage II
Stage III
Stage I
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Justinian R. NgaizaTidalHealth Richard A Henson Cancer Institute9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
4 reported clinical trials
5 drugs studied
John R. MansuetiTidalHealth Richard A Henson Cancer Institute7 years of reported clinical research
Studies Adenocarcinoma
Studies Prostate Cancer
3 reported clinical trials
9 drugs studied
Zeinab Abou YehiaTidalHealth Richard A Henson Cancer Institute3 years of reported clinical research
Studies Cancer
Studies Small Cell Carcinoma
2 reported clinical trials
5 drugs studied
Steven Hearne, MDTidal Health2 years of reported clinical research
Studies Cardiovascular Disease
Studies Vascular Disease
2 reported clinical trials
2 drugs studied
Clinical Trials running at Peninsula Regional Medical Center
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
ALK Gene Rearrangement
Small Cell Carcinoma
Breast Cancer
Cardiovascular Disease
Brain Metastasis
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Peninsula Regional Medical Center?
Peninsula Regional Medical Center is a medical facility located in Salisbury, Maryland. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Peninsula Regional Medical Center is involved with conducting 148 clinical trials across 189 conditions. There are 6 research doctors associated with this hospital, such as Justinian R. Ngaiza, John R. Mansueti, Zeinab Abou Yehia, and Steven Hearne, MD.